Clinical and preclinical development of novel and emerging CAR-T cell therapies for the treatment of solid tumors

¹ OncoImmunology Unit, Navarrabiomed-Fundacion Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Navarra, Spain
² Medical Oncology Unit, Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Navarra, Spain

Academic Editor: Humbert G. Díaz

Published: 05 January 2022 by MDPI in MOL2NET'21, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 7th ed. congress CHEMBIO.ORG-07: Org. Chem., Med. Chem., Mol. Biol., & Pharm. Industry Congress, Paris, France-Galveston, USA, 2021.

https://doi.org/10.3390/mol2net-07-12130 (registering DOI)

Abstract:

Adoptive cell therapy with genetically modified T lymphocytes that express chimeric antigen receptors is one of the most promising advanced therapies for cancer treatment. However, CAR-T cells efficacy in the solid tumor landscape is still very unsatisfactory. The development of a next generation personalized CAR-T treatment and the identification of therapeutic targets to increase the efficacy, survival, persistence, and safety in solid tumors remains as a clinical necessity and a critical frontier in cancer immunotherapy. Here, we summarize the basic, translational and clinical results of CAR-T cell immunotherapy for solid neoplasms, from its preclinical to its clinical development.

Keywords: CAR-T cells, adoptive cell therapy, immunotehrapy, biotechnology, drug development

View paper